Quest Diagnostics Incorporated officer Catherine T. Doherty filed a Form 144 notice on November 3, 2026, proposing the sale of 22,105 shares of common stock acquired through a stock option exercise.

Key Highlights

  • Selling person: Catherine T. Doherty, an officer of Quest Diagnostics Incorporated.
  • Shares proposed for sale: 22,105 shares of common stock, with an aggregate market value of $5,584,607.20.
  • Acquisition method: The shares were acquired through a stock option exercise from the issuer on November 3, 2026, with cash payment on the same date.
  • Shares outstanding: 110,019,073 shares of common stock were reported as outstanding according to the filing.
  • Broker named: Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917, is identified as the broker for the proposed sale.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of August 3, 2026, reflecting reliance on Rule 10b5-1.
  • Prior sales: The filing reports nothing to disclose regarding securities sold during the past three months.

Details of Doherty's Proposed Stock Sale at Quest Diagnostics

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Catherine T. Doherty, identified as an officer of Quest Diagnostics Incorporated (NYSE:DGX), has provided notice of a proposed sale of 22,105 shares of the company's common stock. The filing lists an approximate sale date of November 3, 2026, and names Fidelity Brokerage Services LLC as the executing broker. The aggregate market value of the shares proposed for sale is stated as $5,584,607.20.

The filing discloses that all 22,105 shares were acquired on November 3, 2026, via a stock option exercise from the issuer, with full cash payment made on the same date. Quest Diagnostics is headquartered at 500 Plaza Drive, Secaucus, New Jersey 07094, and its common stock trades on the NYSE. The total number of shares outstanding is reported in the filing as 110,019,073.

Doherty's notice indicates reliance on Rule 10b5-1, with a plan adoption date of August 3, 2026. The filing further states that no sales of Quest Diagnostics securities were made by the selling person during the three months preceding the notice date. The Form 144 was signed by Daniel Tucci as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for Catherine Doherty.

What Was Disclosed

Quest Diagnostics officer Catherine T. Doherty filed a Form 144 notice proposing the sale of 22,105 common shares acquired through a stock option exercise, with an aggregate market value of $5,584,607.20, and citing a Rule 10b5-1 plan adopted on August 3, 2026.